Big pharmaceutical companies are exploring "brand personality" in their marketing strategies, according to new research.
U.S. pharmacy giant Eli Lilly and Company and Denmark's Zealand Pharma are working on new treatments for type 2 diabetes and obesity, the companies announced.
Eli Lilly's experimental Alzheimer's treatment was ruled a failure in two earlier trials. But when investigators combined solanezumab's data from both tests, they discovered that cognitive declines were slowed by 34% among patients who started out with mild symptoms. Based on those results, solanezumab has been selected for a federally sponsored study for people who have not yet suffered significant memory loss.
Alzheimer's researchers got a huge boost last week with the publication of a study showing that a rare genetic mutation prevents the buildup of beta amyloid in the brain.